Cellectar Biosciences Stock (NASDAQ:CLRB)

Forecast Ownership Financials Chart Transcripts

Previous Close

$4.00

52W Range

$3.53 - $66.00

50D Avg

$4.95

200D Avg

$7.22

Market Cap

$11.46M

Avg Vol (3M)

$185.84K

Beta

0.59

Div Yield

CLRB Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 10, 2005

Website

CLRB Performance

CLRB Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-51.78M	$-38.96M	$-28.81M
Net Income	$-44.58M	$-37.98M	$-28.60M
EBITDA	$-51.78M	$-38.77M	$-28.67M
Basic EPS	$-1.22	$-3.11	$-4.05
Diluted EPS	$-1.20	$-3.11	$-4.05

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 14, 25 | 8:30 AM

Q1 25May 13, 25 | 8:30 AM

Q4 24Mar 13, 25 | 8:30 AM

Peer Comparison

Ticker	Company
ASBP	Aspire Biopharma Holdings, Inc.
MBRX	Moleculin Biotech, Inc.
SNSE	Sensei Biotherapeutics, Inc.
ICU	SeaStar Medical Holding Corporation
NXTC	NextCure, Inc.
ATHA	Athira Pharma, Inc.
GOVX	GeoVax Labs, Inc.
CTXR	Citius Pharmaceuticals, Inc.
GLTO	Galecto, Inc.
PALI	Palisade Bio, Inc.